Navigation Links
Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals' Lorcaserin Achieved Statistically Significant Weight Loss
Date:5/26/2011

disease that typically makes weight loss more difficult to achieve.

Changes in secondary endpoints of cardiovascular and metabolic risk were assessed in the Phase 3 program. Body Mass Index (BMI), waist circumference, triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, systolic blood pressure, diastolic blood pressure, heart rate and quality of life were measured in all three trials in the Phase 3 program, and the integrated Year 1 results showed favorable statistically significant effects with lorcaserin 10 mg BID treatment compared to placebo. Lorcaserin did not increase heart rate or blood pressure; changes from baseline for patients who took lorcaserin 10 mg BID, lorcaserin 10 mg QD or placebo, respectively, were as follows: systolic blood pressure (mmHg), (-0.9, -0.2, -0.2); diastolic blood pressure (mmHg), (-1.4, -0.5, -0.8); and heart rate (bpm), (-1.0, -0.5, -0.2).

The most frequent lorcaserin-associated adverse events included headache, nausea, dizziness, fatigue and dry mouth. Headache was the only adverse event with an incidence that exceeded the placebo group by greater than 5%. In each trial, echocardiograms were performed at baseline and every six months to measure heart valve regurgitation. In the meta-analysis of the three trials, the proportion of patients who developed FDA-defined valvulopathy (moderate or greater mitral insufficiency and/or mild or greater aortic insufficiency) at Week 52 were as follows: lorcaserin 10 mg BID (2.37%), lorcaserin 10 mg QD (1.57%) and placebo (2.04%).

"There is a significant unmet need for effective treatment options that can help patients reduce their weight and improve their health in a well-tolerated manner," said William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer. "A diverse group of patients received lorcaserin in our Phase 3 program and achieved clinically meaningful weight loss and improvements in important cardiovascular and metabolic para
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
2. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
3. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
4. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
5. KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain
6. Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data
7. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
8. Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA
9. EntreMed ENMD-2076 Phase 2 Data to Be Presented at ASCO Annual Meeting
10. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
11. Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014   BioNano Genomics announced today achievement of ... collect human data at 30X depth, sufficient for a genome ... capability was established and demonstrated for the IrysChip TM ... System and will be rolled out to BioNano,s collaborators ... showcasing this advancement at the American Society for Human ...
(Date:10/20/2014)... 2014 Pharmaceutic Labs announces the opening of ... Albany, NY for admixing, compounding, drug shortages ... exceeds the FDA standards for safety and quality, using ... The 10,000 square foot outsourcing facility ... assurance and quality control. The company will produce sterile ...
(Date:10/19/2014)... 20, 2014 Shire plc (LSE: SHP, NASDAQ: ... Chief Financial Officer (CFO), has notified the Board of Directors of ... a new career opportunity as CFO of Severn Trent plc.  James ... company will commence a search for a new CFO immediately. ... has helped build and lead a high-quality finance team at Shire. ...
Breaking Medicine Technology:BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... ANTONIO, Oct. 6 Nautilus Neurosciences, Inc., ... Pharmacal Company, a privately-held pharmaceutical company focused ... their exclusive co-promotion agreement for CAMBIA™ (diclofenac ... and other women,s health medical professionals. CAMBIA™ ...
... Gerresheimer Reports Strong Earnings and Sales Growth -- DUSSELDORF, Germany, October 6, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 2Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 3Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 4Gerresheimer Reports Strong Earnings and Sales Growth 2Gerresheimer Reports Strong Earnings and Sales Growth 3Gerresheimer Reports Strong Earnings and Sales Growth 4Gerresheimer Reports Strong Earnings and Sales Growth 5Gerresheimer Reports Strong Earnings and Sales Growth 6Gerresheimer Reports Strong Earnings and Sales Growth 7Gerresheimer Reports Strong Earnings and Sales Growth 8Gerresheimer Reports Strong Earnings and Sales Growth 9
(Date:10/20/2014)... Fort Collins, CO (PRWEB) October 20, 2014 ... platform, dGH assays are the only imaging assays ... data in a single test.  With these three ... in their ability to detect the widest range ... chromosomal translocations—mutations usually missed by other genomic tools, ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Unveiled at the ... Strategic Direction Scorecard conservatively estimates member hospital ROI on membership ... on dues, The Center provides $12.50 in value to member ... (Member Value – Member Dues)/Member Dues. , “This is ... this number and we think the methodology is really sound,” ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... his innovative True Form Tummy Tuck® method ... faculty at The University of Texas Medical Branch ... a medical student. Patronella, who is a founding partner ... practices in Texas, The Aesthetic Center for Plastic ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently announced ... the best Dedicated Server Hosting suppliers. Their websites ... buy high quality hosting and save money at ... Top10BestSEOHosting.com says, “We believe that iPage and GreenGeeks ... lot of the global clients enjoy using their ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 This ... for Partial Seizure, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ... Seizure and special features on late-stage and discontinued ...
Breaking Medicine News(10 mins):Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4
... running, jogging on physical health have been known for a ... Germany that running can improve the mental health status as ... // ,The study participants had to complete a minimum of ... had to take up progressively difficult tests. The researchers examined ...
... has been lifted on account of no single case of bird ... racing, falconry and other bird shows were regularly conducted in Britain.// ... which was detected in Eastern Europe the events were banned to ... of bird flu was reported the health officials are planning to ...
... of two drugs in a rare medical trail. These drugs ... ,They are anti-retroviral drugs which have been studied individually ... are unapproved for the usage in AIDS patient and hence ... usage of this new unapproved AIDS drug started nine months ...
... human cancer cells in a unique way will be ... Zealand. The clinical trial would be held at New ... on Wednesday. ,Auckland University cancer researcher Professor Bill ... is converted to a DNA damaging agent in the ...
... treatment of Ambylopia or lazy eye as it is commonly called. ... at the USC and three other Chinese universities. //,A ... compromise in the vision even when corrective glasses are used. If ... condition has been regarded to be incurable in children over 8 ...
... says that elderly white women who have had non-melanoma skin ... of their exposure to the harmful rays of the sun. ... age group of 50 to 79, who had a previous ... the skin, had a two-fold increase in the risk of ...
Cached Medicine News:Health News:Health Canada Gave Access To Unapproved Drugs To AIDS/HIV Patients. 2
... Our new oversized wheelchair scales incorporate all ... model including automatic zero, weight recall, reweigh ... displays weight in pounds and kilos., ... patients in electric and oversized wheelchairs. The ...
This high-capacity stand-on scale provides extra sensitivity and support to patients who are unsteady on their feet. Advanced technology compensates for patient movement....
... Endo-PAT2000 is a simple and easy to ... PAT signal is recorded using Itamar Medical's ... is analyzed automatically using proprietary advanced Digital ... within seconds of completing the test. The ...
... C-peptide of insulin is the C-terminal cleavage ... prohormone to the mature insulin molecule. Although ... it does undergo significant liver or extra-renal ... circulating half-life than insulin [1]. In addition, ...
Medicine Products: